Almirall Croissance future
Future contrôle des critères 4/6
Almirall devrait augmenter ses bénéfices et son chiffre d'affaires de 28% et de 8.4% par an respectivement. Le BPA devrait croître de de 22% par an. Le rendement des capitaux propres devrait être 10% dans 3 ans.
Informations clés
28.0%
Taux de croissance des bénéfices
21.96%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 20.3% |
| Taux de croissance des recettes | 8.4% |
| Rendement futur des capitaux propres | 10.02% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 22 May 2026 |
Mises à jour récentes de la croissance future
Article d’analyse • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Article d’analyse • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Recent updates
Mise à jour du récit • Feb 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.Mise à jour du récit • Jan 19
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.Mise à jour du récit • Jan 05
ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.Mise à jour du récit • Dec 17
ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Article d’analyse • Dec 08
Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...Mise à jour du récit • Dec 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.Mise à jour du récit • Nov 19
ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Article d’analyse • Nov 17
Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Article d’analyse • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Article d’analyse • Aug 19
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Nouveau récit • Jul 22
European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Article d’analyse • May 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Article d’analyse • Mar 27
Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Article d’analyse • Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...Article d’analyse • Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Article d’analyse • Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Article d’analyse • Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Article d’analyse • Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Article d’analyse • Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Article d’analyse • Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Article d’analyse • Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...Article d’analyse • Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Key Insights Almirall's estimated fair value is €11.37 based on 2 Stage Free Cash Flow to Equity Current share price of...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 1,486 | 157 | 231 | 323 | 9 |
| 12/31/2027 | 1,365 | 122 | 176 | 274 | 11 |
| 12/31/2026 | 1,230 | 85 | 144 | 232 | 11 |
| 3/31/2026 | 1,121 | 40 | 49 | 196 | N/A |
| 12/31/2025 | 1,115 | 46 | 37 | 174 | N/A |
| 9/30/2025 | 1,085 | 42 | 30 | 201 | N/A |
| 6/30/2025 | 1,054 | 21 | 24 | 152 | N/A |
| 3/31/2025 | 1,028 | 24 | 5 | 164 | N/A |
| 12/31/2024 | 991 | 10 | -1 | 161 | N/A |
| 9/30/2024 | 953 | -45 | -23 | 149 | N/A |
| 6/30/2024 | 932 | -35 | -115 | 103 | N/A |
| 3/31/2024 | 915 | -39 | -48 | 116 | N/A |
| 12/31/2023 | 899 | -38 | -66 | 93 | N/A |
| 9/30/2023 | 907 | 7 | -23 | 101 | N/A |
| 6/30/2023 | 898 | -11 | 23 | 156 | N/A |
| 3/31/2023 | 882 | -8 | 37 | 154 | N/A |
| 12/31/2022 | 879 | 4 | 39 | 155 | N/A |
| 9/30/2022 | 864 | 9 | 105 | 177 | N/A |
| 6/30/2022 | 856 | 29 | 98 | 180 | N/A |
| 3/31/2022 | 843 | -50 | 82 | 159 | N/A |
| 12/31/2021 | 837 | -41 | 163 | 234 | N/A |
| 9/30/2021 | 814 | -22 | 204 | 288 | N/A |
| 6/30/2021 | 809 | -11 | 145 | 196 | N/A |
| 3/31/2021 | 790 | 55 | 122 | 198 | N/A |
| 12/31/2020 | 814 | 74 | 36 | 113 | N/A |
| 9/30/2020 | 849 | 63 | 72 | 212 | N/A |
| 6/30/2020 | 872 | 86 | 49 | 194 | N/A |
| 3/31/2020 | 926 | 121 | 158 | 296 | N/A |
| 12/31/2019 | 911 | 106 | N/A | 276 | N/A |
| 9/30/2019 | 858 | 85 | N/A | 190 | N/A |
| 6/30/2019 | 884 | 88 | N/A | 181 | N/A |
| 3/31/2019 | 789 | 80 | N/A | 138 | N/A |
| 12/31/2018 | 811 | 78 | N/A | 143 | N/A |
| 9/30/2018 | 714 | -111 | N/A | 170 | N/A |
| 6/30/2018 | 730 | -179 | N/A | 133 | N/A |
| 3/31/2018 | 687 | -293 | N/A | 82 | N/A |
| 12/31/2017 | 677 | -304 | N/A | 6 | N/A |
| 9/30/2017 | 735 | -128 | N/A | -89 | N/A |
| 6/30/2017 | 755 | -78 | N/A | -13 | N/A |
| 3/31/2017 | 821 | 73 | N/A | 12 | N/A |
| 12/31/2016 | 822 | 75 | N/A | 105 | N/A |
| 9/30/2016 | 778 | 162 | N/A | 151 | N/A |
| 6/30/2016 | 743 | 154 | N/A | 122 | N/A |
| 3/31/2016 | 721 | 111 | N/A | 114 | N/A |
| 12/31/2015 | 738 | 132 | N/A | 171 | N/A |
| 9/30/2015 | 783 | 479 | N/A | 761 | N/A |
| 6/30/2015 | 802 | 488 | N/A | 748 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ALM ( 28% par an) est supérieure au taux d'épargne ( 2.7% ).
Bénéfices vs marché: Les bénéfices de ALM ( 28% par an) devraient croître plus rapidement que le marché Spanish ( 11.6% par an).
Croissance élevée des bénéfices: Les bénéfices de ALM devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ALM ( 8.4% par an) devrait croître plus rapidement que le marché Spanish ( 6.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ALM ( 8.4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ALM devrait être faible dans 3 ans ( 10 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 06:40 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Almirall, S.A. est couverte par 27 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |